TransCode Therapeutics, Inc.
RNAZ
$6.73
-$0.27-3.86%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/7/2026
-
The Cerbat Gem
4/27/2026
-
PR Newswire
4/7/2026
-
TipRanks Financial Blog
4/7/2026
-
The Fly
4/7/2026
-
PR Newswire
4/3/2026
-
Ticker Report
4/1/2026
-
TipRanks Financial Blog
4/1/2026
-
Ticker Report
3/3/2026
-
The Fly
2/23/2026
-
PR Newswire
2/5/2026
-
TipRanks Financial Blog
2/5/2026
-
PR Newswire
1/6/2026
-
GuruFocus
1/6/2026
-
GuruFocus
1/6/2026
-
The Fly
1/6/2026
-
PR Newswire
12/22/2025
-
GuruFocus
12/22/2025
-
PR Newswire
12/12/2025
-
The Fly
12/11/2025
-
GuruFocus
12/11/2025
-
GuruFocus
12/11/2025
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, April 15, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of Aug 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
857 837 3099
Address
6 Liberty Square
Boston, MA 02109
Boston, MA 02109
Country
Year Founded
Business Description
Sector
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company’s lead therapeutic...
more